Phase II, 2nd Line Melanoma - RAND Monotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Melanoma
Interventions
DRUG

Anti-CD137 (4-1BB) (BMS-663513)

IV solution, IV, until PD or toxicity

Trial Locations (32)

8000

Local Institution, Aarhus C

10021

Mem Sloan-Ket Can Ctr, New York

16132

Local Institution, Genove

20141

Local Institution, Milan

21237

Harry & Jeanette Weinberg Cancer Inst At Franklin Square, Baltimore

24105

Local Institution, Kiel

28204

Blumenthal Cancer Center, Carolinas Medical Center, Charlotte

35128

Local Institution, Padua

46202

Indiana University Melvin And Bren Simon Cancer Center, Indianapolis

53100

Local Institution, Siena

54511

Local Institution, Vandœuvre-lès-Nancy

55131

Local Institution, Mainz

59037

Local Institution, Lille

60068

Oncology Specialists, S.C., Park Ridge

66421

Local Institution, Homburg / Saar

68167

Local Institution, Mannheim

72076

Local Institution, Tübingen

75010

Local Institution, Paris

75651

Local Institution, Paris

77030

University Of Texas, Houston

80131

Local Institution, Napoli

90025

The Angeles Clinic & Research Institute, Los Angeles

94805

Local Institution, Villejuif

97080

Local Institution, Würzburg

97213

Providence Portland Medical Center, Portland

06520

Yale University School Of Medicine, New Haven

02115

Dana-Farber Cancer Inst, Boston

T2N 4N2

Local Institution, Calgary

T6G 1Z2

Local Institution, Edmonton

H4J 1C5

Local Institution, Montreal

DK-5000

Local Institution, Odense C

07740

Local Institution, Jena

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00612664 - Phase II, 2nd Line Melanoma - RAND Monotherapy | Biotech Hunter | Biotech Hunter